SWOG clinical trial number
S9800

A Phase II Pilot Trial of CHOP Followed by Rituximab Chimeric Monoclonal Anti-CD20 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphomas

Closed
Phase
II
Accrual
100%
Published
Abbreviated Title
CHOP x 6 followed by Rituximab chimeric monoclonal Anti-CD20 antibody X 4
Activated
02/15/1998
Closed
11/15/1998
Participants
NCORP, Members, Medical Oncologists, Pathologists

Research committees

Lymphoma

Treatment

Rituximab CHOP

Eligibility Criteria Expand/Collapse

Previously untreated follicular center cell Non-Hodgkin's lymphoma (Grade I, II, or III); Stage III, IV, or bulky Stage II disease; bidimensionally measurable disease; lymphomas must express the CD20 antigen; no prior chemotherapy or RT for lymphoma; no prior monoclonal antibodies; bone marrow and biopsy; CT scan of chest, abdomen and pelvis; LDH, B2 micoglobulin; EKG; no impaired cardiac status; no central nervous system involvement; no HIV.

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

2015

Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies

J Kelly;G Salles;B Goldman;RI Fisher;O Casasnovas;O Press;DG Maloney;P Soubeyran;L Rimsza;M Leblanc;H Tilly;J Friedberg Journal of Clinical Oncology May 1;33(13):1482-1490

PMid: PMID25823738 | PMC number: PMC4404425

Elevated serum levels of IL-2R, IL-1RA and CXCL9 are associated with a poor prognosis in follicular lymphoma

M Mir;MJ Mauer;SC Ziesmer;S Slager;T Habermann;W Macon;BK Link;S Syrbu;T Witzig;J Friedberg;O Press;M Leblanc;J Cerhan;A Novak;S Ansell Blood Feb 5;125(6):992-998

PMid: PMID25422100 | PMC number: PMC4319239

2012

Fc gamma receptor 3a genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

D Persky;D Dornan;B Goldman;R Braziel;R Fisher;M LeBlanc;DG Maloney;OW Press;TP Miller;L Rimsza Haematologica 97(6):937-942

PMid: PMID22271896 | PMC number: PMC3366663

Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation and replication in SWOG and LYSA

JL Kelly;G Salles;B Goldman;R Fisher;O Casasnovas;O Press;D Maloney;P Soubeyran;L Rimsza;M Leblanc;H Tilly;J Friedberg Blood 120(21):abst.2712; American Society of Hematology, poster;

2010

Prognostic value of regulatory T-cells, lymphoma associated macrophages and Mum-11 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study [PMC2875547; PMID19875761]

JW Sweetenham;B Goldman;M LeBlanc;JR Cook;RR Tubbs;OW Press;DG Maloney;RI Fisher;LM Rimsza;ED Hsi Annals of Oncology 21(6):1196-1202;

2009

Fc gamma receptor 3a genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

DO Persky;D Dornan;B Goldman;M LeBlanc;RM Braziel;RI Fisher;D Maloney;T Miller;OW Press;LM Rimsza Blood 114:abst.#111 (ASH Annual Meeting, oral presentation)

2008

Stromal gene signatures in large-B-cell lymphomas [PMID19038878]

G Lenz;G Wright;S Dave;W Xiao;J Powell;H Zhao;W Xu;B Tan;N Goldschmidt;J Iqbal;J Vose;M Bast;K Fu;D Weisenburger;T Greiner;JO Armitage;A Kyle;L May;R Gascoyne;JM Connors;G Troen;H Holte;S Kvaloy;D Kierickx;G Verhoef;J Delabie;E Smeland;P Jares;A Martinez;A Lopez-Guillermo;E Montsarrat;E Campo;R Braziel;TP Miller;LM Rimsza;JR Cook;B Pohlman;JW Sweetenham;RR Tubbs;RI Fisher;E Hartmann;A Rosenwald;G. Ott;HK Muller-Hermelink;D Wrench;T Lister;E Jaffe;W Wilson;W Chan;L Staudt New England Journal of Medicine 359(22)2313-2323

Non-hodgkins lymphoma

R Fisher;P Mauch;J Friedberg;L Rimsza In Cancer: Principles and Practice of Oncology, 8th edition, Lippincott, Williams & Wilkins, Baltimore, MD, pp 2098-2158, 2008

MUM1 expression in follicular lymphoma is a poor prognostic marker in patients treated with immunochemotherapy (SWOG 9800/9911) but not chemotherapy alone (SWOG 8809): A Southwest Oncology Group correlative science study

ED Hsi;B Goldman;LM Rimsza;JR Cook;RR Tubbs;OW Press;DG Maloney;RI Fisher;JW Sweetenham Blood 112(11):146, abst. 376

2005

New treatment options have changed the survival of patients with follicular lymphoma

RI Fisher;M LeBlanc;OW Press;DG Maloney;JM Unger;TP Miller Journal of Clinical Oncology 23(33):8447-8452

2004

FC receptor polymorphisms do not influence progression free survival (PFS) of follicular NHL patients treated with CHOP followed by rituximab (SWOG 9800)

DG Maloney;B Pender-Smith;JM Unger;RM Braziel;J Radich;OW Press;TP Miller;TM Grogan;M LeBlanc;RI Fisher Blood 104(11): #589

2001

A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800

DG Maloney;OW Press;RM Braziel;JM Unger;ML LeBlanc;TM Grogan;TP Miller;RI Fisher Blood 98(11):843a(#3502)

Other Clinical Trials

SWOG Clinical Trial Number
SWOG-7204/7205

Non-Hodgkin's Lymphoma CHOP vs. HOP Combination Chemotherapy for Remission Induction and COP vs. OAP Combination Chemotherapy for Maintenance

Research Committee(s)
Lymphoma
Activated
04/17/1972
Closed
09/10/1974
Closed
Phase
III
Published
SWOG Clinical Trial Number
SWOG-7426/7427
SWOG Clinical Trial Number
SWOG-7713/14